These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 24249714)
1. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Wang J; Chen J; Miller DD; Li W Mol Cancer Ther; 2014 Jan; 13(1):16-26. PubMed ID: 24249714 [TBL] [Abstract][Full Text] [Related]
2. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice. Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951 [TBL] [Abstract][Full Text] [Related]
3. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Shi H; Kong X; Ribas A; Lo RS Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746 [TBL] [Abstract][Full Text] [Related]
4. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
5. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471 [TBL] [Abstract][Full Text] [Related]
6. Rescue of cell cycle progression in BRAF Toress-Collado AX; Nazarian R; Jazirehi AR Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920 [TBL] [Abstract][Full Text] [Related]
7. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A J Transl Med; 2011 May; 9():76. PubMed ID: 21609436 [TBL] [Abstract][Full Text] [Related]
9. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329 [TBL] [Abstract][Full Text] [Related]
10. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432 [TBL] [Abstract][Full Text] [Related]
11. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. Peng U; Wang Z; Pei S; Ou Y; Hu P; Liu W; Song J Oncol Rep; 2017 Feb; 37(2):1270-1276. PubMed ID: 28035401 [TBL] [Abstract][Full Text] [Related]
12. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2. Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318 [TBL] [Abstract][Full Text] [Related]
14. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
15. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas. Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867 [TBL] [Abstract][Full Text] [Related]
16. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells. Bauer D; Werth F; Nguyen HA; Kiecker F; Eberle J Cell Death Dis; 2017 Feb; 8(2):e2594. PubMed ID: 28151482 [TBL] [Abstract][Full Text] [Related]
17. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor. Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109 [TBL] [Abstract][Full Text] [Related]
18. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796 [TBL] [Abstract][Full Text] [Related]
19. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
20. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]